| Project/Area Number |
19591923
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
OKI Akinori University of Tsukuba, 大学院・人間総合科学研究科, 教授 (60334067)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIKAWA Hiroyuki 筑波大学, 大学院・人間総合科学研究科, 教授 (40158415)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2007: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 卵巣癌 / 細胞株 / 抗癌剤感受性 / パクリタキセル / 抗癌剤高感受性 / 抗癌剤感受性検査 |
|---|
| Research Abstract |
Although CBDCA/Paclitaxel(PTX) therapy(CP therapy), or new anti-neoplastic agents such as topotecan and doxil contribute to some improvement on the survival of advanced ovarian carcinomas, it is far from complete control of the disease. However, many of us have been experienced dramatic clinical complete response(CR) cases that resulted to be cured by intensive combination therapy. This is a streak of hope for not only patients, but us as the cancer therapists. A novel cell line, named Opt203 was established from a patient who was suffered from IV stage ovarian carcinoma and successfully treated with 10 courses of CP therapy and two times of interval cytoreductive surgeries, resulted to complete response and maintained the status of no evidence of recurrence(NER) for 20 months. In the study of the characterization of this cell line, we found that Opt203 was very chemo-sensitive against many anti-neoplastic agents, especially paclitaxel(PTX). This result is closely concerned to the clinical course of the original patient. Thus Opt203 line was regarded as "real PTX-sensitive" cell line, and would be a bench mark of PTX sensitive cell line in vitro.
|
